Agenda
This agenda is the latest draft and subject to change. We are working on further details and will update this page as soon as possible.
*All times are in CEST
Sep
Fri 26
Welcome reception
Sep
Sat 27
Introduction & Meeting Objectives
John Gribben
Session 1: T-cell Leukemia/Lymphoma
Chairs: Laurence de Leval & Francine Foss
Special Lecture: T-cell Leukemia/Lymphoma
- Talks to be confirmed
Panel Discussion
Break
Session 2: Session II: MCL
Chairs: Stephen Ansell & TBC
- Further details to be confirmed
Panel Discussion
Session 3: Keynote address
Chair & Introduction:tbc
Keynote speaker: Margaret Shipp
Panel Discussion
Lunch
Session 4: Novel therapies I
Chairs: Jason Westin & Laurie Sehn
Industry Panel Discussion: Simon Rule
MRD-driven endpoints
ADCs:
- Further details to be confirmed
Panel Discussion
Break
Session 5: Special Topic: Hodgkin’s Lymphoma
Chairs: Peter Borchmann & Ranjana Advani
- Further details to be confirmed
Panel Discussion
Special topic: MRD-driven endpoints; Nicole Gormley (FDA)
Day 1 Wrap Up
Sep
Sun 28
Session 6: BsAb’s for NHL
Chairs: Martin Hutchings & Marion Subklewe
CD3/CD20 bispecifics and their quest for ideal partners
- Further information to be confirmed
Panel Discussion
Bispecific and trispecifics with other formats and targets
- Further information to be confirmed
Panel Discussion
Break
Session 7: Novel Therapies II
Chairs: Laurie Sehn & Alexey Danilov
- BTK Inhibitors
- BTK Degraders
- BCL-2 inhibitors
Panel Discussion
Lunch
Session 8: Expanding the CAR platform for NHL
Chairs: David Maloney & Catherine Bollard
- Further information to be confirmed
Panel Discussion
Final Meeting Summary and Conclusions
Chairs: iwNHL Committee
